1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Market Analysis by Type
  • 1.3.1 Overview: Global Zolbetuximab Consumption Value by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 100 mg / bottle
  • 1.3.3 300 mg / bottle
• 1.4 Market Analysis by Dosage Form
  • 1.4.1 Overview: Global Zolbetuximab Consumption Value by Dosage Form: 2021 Versus 2025 Versus 2032
  • 1.4.2 Lyophilized Powder for Injection
  • 1.4.3 2 Class Two Zolbetuximab 静脉输注用制剂 3 Class Three Zolbetuximab 4 Class Four Zolbetuximab 5 Class Five Zolbetuximab 6 Class Six Zolbetuximab 7 Class Seven Zolbetuximab 8 Class Eight Zolbetuximab 9 Class Nine Zolbetuximab 10 Class Ten Zolbetuximab
• 1.5 Market Analysis by Route of Administration
  • 1.5.1 Overview: Global Zolbetuximab Consumption Value by Route of Administration: 2021 Versus 2025 Versus 2032
  • 1.5.2 Intravenous Infusion
  • 1.5.3 Intravenous Injection
• 1.6 Market Analysis by Combination Therapy
  • 1.6.1 Overview: Global Zolbetuximab Consumption Value by Combination Therapy: 2021 Versus 2025 Versus 2032
  • 1.6.2 Combination With Immunotherapy
  • 1.6.3 Combination With Anti-Angiogenic Agents
• 1.7 Market Analysis by Application
  • 1.7.1 Overview: Global Zolbetuximab Consumption Value by Application: 2021 Versus 2025 Versus 2032
  • 1.7.2 Gastric Cancer
  • 1.7.3 Gastroesophageal Junction Cancer
  • 1.7.4 Advanced Gastrointestinal Malignancies
  • 1.7.5 Others
• 1.8 Global Zolbetuximab Market Size & Forecast
  • 1.8.1 Global Zolbetuximab Consumption Value (2021 & 2025 & 2032)
  • 1.8.2 Global Zolbetuximab Sales Quantity (2021-2032)
  • 1.8.3 Global Zolbetuximab Average Price (2021-2032)

2 Manufacturers Profiles

• 2.1 Astellas Pharma
  • 2.1.1 Astellas Pharma Details
  • 2.1.2 Astellas Pharma Major Business
  • 2.1.3 Astellas Pharma Zolbetuximab Product and Services
  • 2.1.4 Astellas Pharma Zolbetuximab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 Astellas Pharma Recent Developments/Updates

3 Competitive Environment: Zolbetuximab by Manufacturer

• 3.1 Global Zolbetuximab Sales Quantity by Manufacturer (2021-2026)
• 3.2 Global Zolbetuximab Revenue by Manufacturer (2021-2026)
• 3.3 Global Zolbetuximab Average Price by Manufacturer (2021-2026)
• 3.4 Market Share Analysis (2025)
  • 3.4.1 Producer Shipments of Zolbetuximab by Manufacturer Revenue ($MM) and Market Share (%): 2025
  • 3.4.2 Top 3 Zolbetuximab Manufacturer Market Share in 2025
  • 3.4.3 Top 6 Zolbetuximab Manufacturer Market Share in 2025
• 3.5 Zolbetuximab Market: Overall Company Footprint Analysis
  • 3.5.1 Zolbetuximab Market: Region Footprint
  • 3.5.2 Zolbetuximab Market: Company Product Type Footprint
  • 3.5.3 Zolbetuximab Market: Company Product Application Footprint
• 3.6 New Market Entrants and Barriers to Market Entry
• 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

• 4.1 Global Zolbetuximab Market Size by Region
  • 4.1.1 Global Zolbetuximab Sales Quantity by Region (2021-2032)
  • 4.1.2 Global Zolbetuximab Consumption Value by Region (2021-2032)
  • 4.1.3 Global Zolbetuximab Average Price by Region (2021-2032)
• 4.2 North America Zolbetuximab Consumption Value (2021-2032)
• 4.3 Europe Zolbetuximab Consumption Value (2021-2032)
• 4.4 Asia-Pacific Zolbetuximab Consumption Value (2021-2032)
• 4.5 South America Zolbetuximab Consumption Value (2021-2032)
• 4.6 Middle East & Africa Zolbetuximab Consumption Value (2021-2032)

5 Market Segment by Type

• 5.1 Global Zolbetuximab Sales Quantity by Type (2021-2032)
• 5.2 Global Zolbetuximab Consumption Value by Type (2021-2032)
• 5.3 Global Zolbetuximab Average Price by Type (2021-2032)

6 Market Segment by Application

• 6.1 Global Zolbetuximab Sales Quantity by Application (2021-2032)
• 6.2 Global Zolbetuximab Consumption Value by Application (2021-2032)
• 6.3 Global Zolbetuximab Average Price by Application (2021-2032)

7 North America

• 7.1 North America Zolbetuximab Sales Quantity by Type (2021-2032)
• 7.2 North America Zolbetuximab Sales Quantity by Application (2021-2032)
• 7.3 North America Zolbetuximab Market Size by Country
  • 7.3.1 North America Zolbetuximab Sales Quantity by Country (2021-2032)
  • 7.3.2 North America Zolbetuximab Consumption Value by Country (2021-2032)
  • 7.3.3 United States Market Size and Forecast (2021-2032)
  • 7.3.4 Canada Market Size and Forecast (2021-2032)
  • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

• 8.1 Europe Zolbetuximab Sales Quantity by Type (2021-2032)
• 8.2 Europe Zolbetuximab Sales Quantity by Application (2021-2032)
• 8.3 Europe Zolbetuximab Market Size by Country
  • 8.3.1 Europe Zolbetuximab Sales Quantity by Country (2021-2032)
  • 8.3.2 Europe Zolbetuximab Consumption Value by Country (2021-2032)
  • 8.3.3 Germany Market Size and Forecast (2021-2032)
  • 8.3.4 France Market Size and Forecast (2021-2032)
  • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
  • 8.3.6 Russia Market Size and Forecast (2021-2032)
  • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

• 9.1 Asia-Pacific Zolbetuximab Sales Quantity by Type (2021-2032)
• 9.2 Asia-Pacific Zolbetuximab Sales Quantity by Application (2021-2032)
• 9.3 Asia-Pacific Zolbetuximab Market Size by Region
  • 9.3.1 Asia-Pacific Zolbetuximab Sales Quantity by Region (2021-2032)
  • 9.3.2 Asia-Pacific Zolbetuximab Consumption Value by Region (2021-2032)
  • 9.3.3 China Market Size and Forecast (2021-2032)
  • 9.3.4 Japan Market Size and Forecast (2021-2032)
  • 9.3.5 South Korea Market Size and Forecast (2021-2032)
  • 9.3.6 India Market Size and Forecast (2021-2032)
  • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
  • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

• 10.1 South America Zolbetuximab Sales Quantity by Type (2021-2032)
• 10.2 South America Zolbetuximab Sales Quantity by Application (2021-2032)
• 10.3 South America Zolbetuximab Market Size by Country
  • 10.3.1 South America Zolbetuximab Sales Quantity by Country (2021-2032)
  • 10.3.2 South America Zolbetuximab Consumption Value by Country (2021-2032)
  • 10.3.3 Brazil Market Size and Forecast (2021-2032)
  • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

• 11.1 Middle East & Africa Zolbetuximab Sales Quantity by Type (2021-2032)
• 11.2 Middle East & Africa Zolbetuximab Sales Quantity by Application (2021-2032)
• 11.3 Middle East & Africa Zolbetuximab Market Size by Country
  • 11.3.1 Middle East & Africa Zolbetuximab Sales Quantity by Country (2021-2032)
  • 11.3.2 Middle East & Africa Zolbetuximab Consumption Value by Country (2021-2032)
  • 11.3.3 Turkey Market Size and Forecast (2021-2032)
  • 11.3.4 Egypt Market Size and Forecast (2021-2032)
  • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
  • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

• 12.1 Zolbetuximab Market Drivers
• 12.2 Zolbetuximab Market Restraints
• 12.3 Zolbetuximab Trends Analysis
• 12.4 Porters Five Forces Analysis
  • 12.4.1 Threat of New Entrants
  • 12.4.2 Bargaining Power of Suppliers
  • 12.4.3 Bargaining Power of Buyers
  • 12.4.4 Threat of Substitutes
  • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

• 13.1 Raw Material of Zolbetuximab and Key Manufacturers
• 13.2 Manufacturing Costs Percentage of Zolbetuximab
• 13.3 Zolbetuximab Production Process
• 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

• 14.1 Sales Channel
  • 14.1.1 Direct to End-User
  • 14.1.2 Distributors
• 14.2 Zolbetuximab Typical Distributors
• 14.3 Zolbetuximab Typical Customers

15 Research Findings and Conclusion

16 Appendix

• 16.1 Methodology
• 16.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Zolbetuximab market size was valued at US$ 432 million in 2025 and is forecast to a readjusted size of US$ 2557 million by 2032 with a CAGR of 17.4% during review period.
Zolbetuximab is a recombinant, chimeric monoclonal antibody directed against Claudin 18.2 (CLDN18.2), a tight junction protein specifically overexpressed in certain gastrointestinal malignancies. It binds selectively to CLDN18.2 on tumor cell surfaces, triggering antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) to induce tumor cell lysis and inhibit tumor progression. Designed for targeted therapy of CLDN18.2-positive advanced solid tumors, it serves as a key targeted agent for gastric and gastroesophageal junction cancers, offering a new treatment option for patients with limited therapeutic choices.In 2025, global Zolbetuximab production reached approximately 410,000–420,000 vials
Zolbetuximab, as the world’s first and only approved monoclonal antibody targeting Claudin 18.2 (CLDN18.2), has established a core market position in the precision treatment of gastric and gastroesophageal junction adenocarcinomas due to its pioneering status. Its commercial value relies on the unique high expression specificity of this target in certain gastrointestinal malignancies and the significant efficacy advantages demonstrated in key clinical trials, opening up a new field for patients with limited responses to traditional treatment regimens. The current market is dominated by the original developer with no direct competing products, allowing it to rapidly set treatment standards and build brand barriers after approval in major global markets. The core driver of market growth stems from the substantial unmet medical need in advanced gastric cancer, as well as the popularization of companion diagnostic technologies and improved patient screening rates. Although high pricing has restricted market accessibility to a certain extent, its market outlook remains broad as a breakthrough therapy. In the future, its market lifecycle will depend on the continuous expansion of indications, deeper penetration into global markets, progress in medical insurance access, and response to the increasingly competitive environment brought by the launch of subsequent drugs targeting the same target, including monoclonal antibodies, ADCs and cell therapies.
This report is a detailed and comprehensive analysis for global Zolbetuximab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Zolbetuximab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Zolbetuximab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Zolbetuximab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Zolbetuximab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Zolbetuximab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Zolbetuximab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Astellas Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Zolbetuximab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
100 mg / bottle
300 mg / bottle
Market segment by Dosage Form
Lyophilized Powder for Injection
2 Class Two Zolbetuximab 静脉输注用制剂 3 Class Three Zolbetuximab 4 Class Four Zolbetuximab 5 Class Five Zolbetuximab 6 Class Six Zolbetuximab 7 Class Seven Zolbetuximab 8 Class Eight Zolbetuximab 9 Class Nine Zolbetuximab 10 Class Ten Zolbetuximab
Market segment by Route of Administration
Intravenous Infusion
Intravenous Injection
Market segment by Combination Therapy
Combination With Immunotherapy
Combination With Anti-Angiogenic Agents
Market segment by Application
Gastric Cancer
Gastroesophageal Junction Cancer
Advanced Gastrointestinal Malignancies
Others
Major players covered
Astellas Pharma
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Zolbetuximab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Zolbetuximab, with price, sales quantity, revenue, and global market share of Zolbetuximab from 2021 to 2026.
Chapter 3, the Zolbetuximab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Zolbetuximab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Zolbetuximab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Zolbetuximab.
Chapter 14 and 15, to describe Zolbetuximab sales channel, distributors, customers, research findings and conclusion.